ProCE Banner Activity


Advances in Gynecologic Cancers: A New Era in Treatment


Until recently, progress in the management of gynecologic cancers had been slow with poor prognosis and low survival rates for advanced/metastatic disease. Recent FDA approvals have led to a paradigm shift in treatment for several gynecologic cancers including, endometrial, ovarian, and cervical cancers. Of importance, the swift emergence of novel agents has meant that healthcare professionals may not be familiar with use of new therapies in clinical practice and the prevention and management of their associated toxicities. In this video lecture, 2 gynecologic oncology experts discuss strategies for optimizing the use of novel and emerging therapies for advanced gynecologic cancers, including PARP inhibitor therapy for ovarian cancer, immunotherapies in endometrial cancer, and individualizing therapy decisions and managing adverse events in cervical cancer.

Physician Assistants: maximum of 1.00 hours of AAPA Category 1 CME credits Registered Nurses: 1.00 Nursing contact hours, includes 1.00 hour of pharmacology credit

Released: August 15, 2022

Expiration: August 14, 2023

No longer available for credit.



Rachel Frankenthal

Rachel Frankenthal, PA-C, MPH

Physician Assistant
Division of Gynecologic Oncology
Department of Obstetrics and Gynecology
University of California, Los Angeles
Los Angeles, California

Ritu Salani

Ritu Salani, MD, MBA

Professor and Division Director
Division of Gynecologic Oncology
Department of Obstetrics and Gynecology
University of California, Los Angeles
Los Angeles, California

Beth Sandy

Beth Sandy, MSN, CRNP

Nurse Practitioner
Abramson Cancer Center
University of Pennsylvania
Philadelphia, Pennsylvania


This activity is supported by educational grants from AstraZeneca; GlaxoSmithKline; and Merck Sharp & Dohme Corp.

Provided by

Provided by Practicing Clinicians Exchange.

ProCE Banner




Merck Sharp & Dohme Corp.

Target Audience

Oncology NPs, PAs, and nurses

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Summarize the evidence for current and emerging therapies for gynecologic cancers

  • Apply strategies to manage toxicities associated with innovative treatments for ovarian, endometrial, and cervical cancers

  • Identify healthcare disparities that can impact the prognosis and optimal management of patients with ovarian, endometrial, and cervical cancers


All faculty and planners participating in continuing education activities sponsored by Practicing Clinicians Exchange (PCE) are required to disclose all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PCE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.

Rachel Frankenthal, PA-C, MPH, has no relevant financial relationships to disclose.

Ritu Salani, MD, MBA: consultant/advisor/speaker: Arcus Biosciences, Genentech, GlaxoSmithKline, Instil Bio, Merck, Regeneron, Seagen.

Beth Sandy, MSN, CRNP: consultant: Amgen, AstraZeneca, Janssen, Jazz, Merck, Takeda.

None of the members of the Planning Committee or PCE staff have any relevant financial relationships to disclose, except Beth Sandy, MSN, CRNP as noted above.

Instructions for Credit

Participants wishing to earn CE/CME credit must:

  1. View the content in its entirety
  2. Relate the content material to the learning objectives
  3. Complete evaluation form

The estimated time to complete this activity is 1.00 hour.

Release date: August 15, 2022
Expiration date: August 14, 2023


On-demand webcast


The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.



Joint Accreditation Statement

Joint AccreditationIn support of improving patient care, Practicing Clinicians Exchange is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

ANCC Credit Designation

NP Course Advisor: Beth Sandy, MSN, CRNP, Abramson Cancer Center, Philadelphia, Pennsylvania

Nursing contact hours: 1.00, which includes 1.00 hour of pharmacology credit

AAPA Credit Designation

Joint AccreditationPracticing Clinicians Exchange has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credit. Approval is valid until August 14, 2023. PAs should only claim credit commensurate with the extent of their participation.

IPCE Credit Designation
IPCEThis activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.

Additional Information

Program Medium

This program has been made available online.